Drug
Danicopan clinical trials
Also written ACH-4471 and ALXN2040.
- studies test it
- 26
- open now
- 1
- in phase 3
- 3
- first study started
- 2016
Keep track of what changes. Save the danicopan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- 4471
- 13
Development codes
Studies by the year they started
26 studies that test it; most in 2018 (7)
| Year | Studies |
|---|---|
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 7 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 8
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 1
Alexion Pharmaceuticals, Inc. (25) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Eculizumab (1) · Rosuvastatin (1) · Cyclosporine (1) · Tacrolimus (1) · Omeprazole (1) · Midazolam (1) · Fexofenadine (1) · Mycophenolic Acid (1)
Studies
Open first, then newest update. How each study uses danicopan is read from its arms, and is right about nine times in ten.
Testing it · 26
- Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular HemolysisRecruitingPhase 3Alexion Pharmaceuticals, Inc.NCT06449001Written as Danicopan
- A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHActive, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT05389449Written as Danicopan
- A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedPhase 2Alexion Pharmaceuticals, Inc.NCT05019521Written as Danicopan
- Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)CompletedPhase 3Alexion Pharmaceuticals, Inc.NCT04469465Written as Danicopan
- Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to EculizumabCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT03472885Written as Danicopan
- A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471TerminatedPhase 2Alexion Pharmaceuticals, Inc.NCT03459443Written as Danicopan
- ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04988035Written as Danicopan
- Potential Drug Interaction Between ALXN2040 and RosuvastatinCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05708573Written as ALXN2040
- A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT03181633Written as ACH-0144471
- A Study of the Effects of Food and Age on DanicopanCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04551599Written as Danicopan
- A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT03369236Written as Danicopan
- Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT03053102Written as Danicopan
- Study of the Metabolism of Danicopan in Healthy AdultsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04609696Written as Danicopan: Powder-In-Capsule 1
- A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy AdultsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05109390Written as Danicopan
- A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGNCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT03124368Written as Danicopan
- A Study of the Cardiac Effects of Danicopan in Healthy AdultsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05016206Written as Danicopan
- Study of Danicopan in Participants With Hepatic ImpairmentCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT03555539Written as Danicopan
- A Study of Modified Release Formulations of Danicopan in Healthy Adult ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT03384186Written as Danicopan Modified Release Prototype 1
- Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04940559Written as Danicopan - Tablet
- A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT03108274Written as Danicopan
Codes
What other systems call danicopan · ClinicalTrials.gg INT001676
- MeSH (NLM) C000718467danicopanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) JM8C1SFX0UDANICOPANConfirmed FDA, NLM, Wikidata
- Wikidata Q124407181danicopanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C148181DanicopanOne source FDA
- DrugBank DB15401One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718467 | danicopan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | JM8C1SFX0U | DANICOPAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q124407181 | danicopan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C148181 | Danicopan | One source FDA |
| DrugBank | DB15401 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.